Effect of metoprolol on myocardial apoptosis after coronary microembolization in rats

Qiang Su, Lang Li, Yang-chun Liu, You Zhou, Wei-ming Wen
Department of Cardiology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

Corresponding Author: Lang Li, Email: drlilang@163.com

INTRODUCTION

Coronary microembolization (CME) is a spontaneous event caused by atherosclerotic plaque rupture in patients with acute coronary syndromes and a potential iatrogenic complication in patients undergoing thrombolytic therapy and coronary intervention.¹⁻³ The incidence is 15%–20%, even up to 30%–45% in great saphenous vein grafts PCI. CME causing transient “no blood flow” or “slow flow” is the independent predictor of long-term poor prognosis in patients with acute myocardial infarction.² Furthermore, CME can also lead to progressive myocardial dysfunction, including overt myocardial infarction, contractile dysfunction, arrhythmias and coronary reserve reduction.⁴⁻⁵ Once CME occurs, clinical outcomes of such patients are not improved by using coronary thrombolysis agents, nitroglycerin and platelet GPIIb/IIIa receptor antagonists or direct thrombectomy.⁶⁻⁷ Therefore, therapy for CME remains an issue and furthermore, the underlying molecular mechanisms of pathophysiology in CME remain to be elucidated.

Clinically, intracoronary β-adrenergic blocker administration before coronary intervention reduces complications caused by CME.⁸ The use of metoprolol before PCI can significantly protect the ischemic...
myocardium from myocardial damage.[9] The intracoronary use of metoprolol can also reduce the occurrence of "no reflow" or "show reflow" phenomenon and improve the short-term and long-term prognosis of patients.[10] Clinical findings show that metoprolol could play its roles of anti-inflammation and anti-apoptosis to improve cardiac function in condition of ischemic cardiomyopathy.[8,11,12] The function of metoprolol in the treatment of CME is not entirely clear, but myocardial apoptosis certainly occurs after CME[13] and metoprolol can inhibit myocardial apoptosis. Therefore, this study aims to observe the effect of metoprolol on myocardial apoptosis and caspase-3 activation after CME in rats, and to explore how metoprolol can prevent myocardial injury caused by CME, and to provide theoretical basis for the clinical prevention and treatment of CME.

METHODS

Animals and reagents

Male Sprague-Dawley rats (200–250 g) were purchased from the Animal Center of Guangxi Medical University. All procedures were performed in accordance with institutional guidelines for animal care and the Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85–23, revised 1996). Microembolization ball (lyophilized power) was purchased from Dynal Corporation, Norway; the diameter of balls was 42 μmol, there was 2×10^6 balls in each gram of powder, and the final density was 3×10^4 balls/mL. Metoprolol was provided by AstraZeneca Laboratories. The monoclonal anti-cleaved caspase-3 antibody was purchased from Cell Signaling Technology (Beverly, MA, USA). The terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay kit was purchased from Roche (Indianapolis, IN, USA).

Modeling and grouping

The 30 rats were randomized into sham-operation (control group), CME plus saline (CME group), and CME plus metoprolol (metoprolol group), 10 rats for each group. The CME model was performed as described previously.[14,15] Briefly, the rats were anesthetized with 10% chloral hydrate (3 mL/kg, i.p.) and the trachea was intubated to maintain ventilation with a respirator. The chest was opened and the ascending aorta was isolated. Then, 3,000 microspheres (42 μm, Dynal, Norway) suspended in 0.1 mL 0.9% saline were rapidly injected into the left ventricle during a 10-second occlusion of the ascending aorta. The occlusion device was removed following injection, and the chest was closed with sutures after the heart rate and breathing rate returned to normal. The rats in the sham-operated control group were given normal saline without microspheres. The rats in the metoprolol group were intravenously given three bolus injections of metoprolol (2.5 mg/kg) at approximately 5-minute intervals at 30 minutes before CME induction; while the CME group was given the same volume of saline as the metoprolol group.

Echocardiography

The rats were lightly anesthetized with an intraperitoneal injection of sodium pentobarbital (30–40 mg/kg) and the left ventricle was examined using echocardiography. Briefly, a 12 MHz transducer was placed on the left anterior chest wall to obtain left ventricle ejection fraction (LVEF), left ventricle end-diastolic dimension (LVEDd), fractional shortening (FS), and cardiac output (CO). All echocardiography was performed by an experienced physician using a Philips Sonos 7500 system (Philips, Andover, USA). Cardiac function evaluation was performed three times, and the average was used for each index.

Tissue sampling

After echocardiography was performed, the heart was arrested in diastole by injecting 2 mL 10% KCl into the tail of the rats. Immediately, the rat heart was detached, the atrial appendage and atrium cordis were removed, and the heart ventricle was segmented into the apex and base parts from the long axis midpoint of the left ventricle along the direction paralleling to the atroventricular groove. The apex part underwent fast freezing in liquid nitrogen, then was stored at –80 °C, waiting for western blot assay. The base part underwent fixation using 4% paraformaldehyde for 12 hours, paraffin embedding, and serial sectioning (4-μm thick; at least 12 pieces of slices), three pieces of slices containing the same number of microinfarction foci were selected for conducting TUNEL assay to detect myocardial apoptosis, and HE staining and HBFP (hematoxylin basic fuchsin picric acid) staining were also preformed on triplicate slices to detect myocardial microinfarction area.

Measuring myocardial microinfarction area

HBFP staining was an important method for the early diagnosis of myocardial ischemia, the ischemic cardiac muscle and red cells were dyed into red color, and the normal myocardial cytoplasm and nuclei were dyed into yellow and blue colors, respectively. Using DMR+Q550 pathological image pattern analysis instrument to analyze slices stained by HBFP, five microscopic visual fields (×100) were randomly sampled from each slice.
for observation, using Leica Qwin analysis software (Germany) and the planar area method to measure the infraction zone, expressing as area percent of bulk analysis slice and averaging.13

**Detecting myocardial apoptosis by TUNEL assay**

The procedure strictly accorded with the description of Kit specification. The optical microscopic apoptotic nuclei displayed yellow brown color (TUNEL positive), a total of 40 non-overlapping zones (400 ×) from each slice were randomly observed, respectively belonging to the microinfraction zone, the marginal zone and the zone far from infraction.10 The myocardial apoptotic number and overall myocardial cell number were counted using the following equation: the myocardial apoptotic rate = apoptotic number/overall cell number ×100%.

**Western blot assay**

To detect the contents of activated caspase-3 in myocardial tissues, antibodies recognizing shear-activated caspase-3 were used in western blot. Using lysis, we extracted buffer myocardial total proteins and the Lowry method was used to measure protein concentration. 10% SDS-PAGE was performed with 50 µg of loading samples. Membrane (PVDF membrane) transfer was conducted at 100 mA current for 2 hours. Membrane was incubated in blocking solution at room temperature (RT) for 1 hour, rinsed by TBST, followed by incubation with primary antibody (cleaved caspase-3, 1:1 000) overnight at 4 °C and then with horseradish peroxidase(HRP) conjugated secondary antibodies (1:2 000) at room temperature for 1 hour. HRP-labeled anti-GAPDH (1:1 000) served as inner control. Following rinsing, the membrane was incubated with the corresponding secondary antibodies for 1 hour. The Bio-Rad Gel Doc 2000 imaging system and software were used to calculate the integrated absorbance (IA) of identified bands: IA = area × average density. After normalizing to GAPDH levels, the ratios of caspase-3 IA to GAPDH IA were used to represent the relative levels of activated caspase-3.

**Statistical analysis**

Data were expressed as mean ± standard deviation. Comparisons were made using an unpaired Student’s t test (two groups) or the analysis of variance (ANOVA, three or more groups) followed by Tukey’s post-hoc test. For linear correlation analysis, Pearson’s product-moment correlation coefficient analysis was made using SPSS software (SPSS, Chicago, Illinois, USA). Statistical significance was set at P<0.05.

**RESULTS**

**General outcomes**

No statistically significant differences (P>0.05) were found in body weight or heart rate between all groups (data not shown).

**Effect of metoprolol treatment on cardiac function in CME rats**

Initially, we measured cardiac function by using echocardiography to determine the effect of metoprolol treatment 6 hours after CME-induced cardiac dysfunction (Table 1). Compared with the control group, the rats in the CME group showed a significant decrease in LVEF, FS, and CO, but an increase in LVEDd (P<0.05), suggesting that cardiac function in rats with CME was impaired. Cardiac function in the metoprolol group was impaired compared with the control group, but it was less impaired compared with the CME group, i.e. LVEF, FS, and CO significantly increased, and LVEDd significantly decreased (P<0.05), showing that metoprolol treatment can somehow improve the cardiac function in CME rats.

**Effect of metoprolol treatment on myocardial infarction size in CME rats**

Microspheres were injected directly into the coronary arteries, and effective CME was evident by histology (Figure 1). However, there was no significant difference (P>0.05) in myocardial infarct size in the metoprolol group compared with the CME group (Figure 2). Infarct areas in the CME and metoprolol groups were 8.32±3.27 and 7.98±2.72, respectively, indicating that metoprolol treatment has no significant effect on myocardial infarction size caused by CME in rats.

**Effect of metoprolol treatment on myocardial apoptosis in CME rats**

As there was no significant difference in myocardial infarction size in the metoprolol group compared with CME group, apoptosis in the rat heart tissues

| Groups | Number | LVEF (%) | FS (%) | CO (L/min) | LVEDd (mm) |
|--------|--------|----------|--------|------------|------------|
| Control| 10     | 82.67±3.50 | 42.97±3.44 | 0.164±0.009 | 5.11±0.33  |
| CME    | 10     | 72.88±3.27  | 37.59±2.49  | 0.102±0.007  | 6.20±0.16  |
| Metoprolol | 10  | 79.97±4.26  | 41.64±2.08  | 0.157±0.014  | 5.34±0.29  |

Compared with the control group, *P<0.05; compared with the CME group, †P=0.05.

www.wjem.org
was assessed using TUNEL staining. Compared with the control group, there were many TUNEL positive (brown) cells in rat tissues of the CME group ($P<0.05$). Metoprolol treatment significantly decreased ($P<0.05$) the relative apoptotic cell proportion following CME. The myocardial apoptotic percentages in the control, CME, and metoprolol groups were 0.20±0.15, 3.17±1.26, and 1.32±0.28, respectively (Figures 3 and 4), indicating that metoprolol treatment can significantly reduce myocardial apoptosis caused by CME in rats.

**Effect of metoprolol on myocardial expression of caspase-3**

Since metoprolol treatment decreased apoptosis in CME rats. Western blot analysis was made of mitochondrial apoptotic pathway proteins, including activated caspase-3 (Figure 5). Compared with the control group, the CME group showed the significantly enhanced expression of activated caspase-3 in myocardial cells of rats ($P<0.05$). Compared with the CME group, the metoprolol group significantly decreased the contents of activated caspase-3 ($P<0.05$). Obviously, metoprolol treatment can reduce apoptosis in CME rats by inhibiting the expression of activated caspased-3.

**Linear correlation analysis**

Linear correlation analysis indicated that the activated caspase-3 is positively correlated with relative apoptotic cell proportion ($r=0.856$, $P=0.029$), demonstrating that caspase-3 is activated during apoptosis and positively correlated with apoptosis in CME rats.
DISCUSSION

Apoptosis plays an important role in myocardial dysfunction. It has been reported that the microembolized myocardium is characterized by perfusion-contraction mismatch, reduced contractile function and unchanged or possibly elevated blood flow. Since cardiomyocytes are non-renewable cells, the loss of cardiomyocytes via apoptosis may play an important role in the progression of myocardial contractile dysfunction. The mechanisms of myocyte cell death include apoptosis and necrosis, with early research confirming that myocyte cell death by apoptosis is likely in the beginning hours of ischemia, and that myocyte cell death by necrosis is evident after long-term ischemia. Although cardiomyocyte apoptosis may directly lead to myocardial dysfunction, it remains unknown whether inhibition of apoptosis is beneficial in CME treatment. Intravenous β-blocker treatment before coronary artery occlusion is capable of reducing myocardial injury. Clinically, administration of intravenous metoprolol could significantly produce heart protective effect in ischemia-reperfusion.

In our preliminary experiment, caspase-3 was activated after CME. The level of caspase-3 peaked at six hours after CME, thereby, this study adopted 6 hours after CME as the time point of observation. Notably, at 6 hours after CME, multiple microinfarction foci appeared in the myocardium, myocardial cells became apoptotic and necrotic, and the cardiac function was decreased.

Caspases, a family of aspartic acid-specific proteases, are the major effectors of apoptosis. Caspases exist as inactive zymogens in cells and undergo a cascade of catalytic activation at the onset of apoptosis. Caspase-3 mediates the pathway to apoptosis protease cascade, as the key protease to mammalian cell apoptosis, the main apoptosis effect factor and the most important apoptosis performer. Intravenous injection of metoprolol before surgery could significantly improve the myocardial apoptosis and systolic dysfunction caused by CME. Molecular biology showed the significantly inhibited caspase-3 protein activation in myocardial tissue, and reduced myocardial apoptosis rate. Cardiac echocardiography revealed systolic dysfunction and the left ventricular dilation manifested by a decrease in LVEF, FS and CO as well as an increase in LVEDd. Since myocardial cells are non-differentiating, inhibition of myocardial apoptosis may be one of the most important mechanisms by which metoprolol therapy improves the prognosis of CME.

In the present study, metoprolol pretreatment significantly improved the cardiac function in CME rats; however no difference in myocardial infarction size was found as compared with the CME group. We determined the effect of metoprolol treatment on myocardial apoptosis in CME rats, and found that metoprolol can significantly reduce myocardial apoptosis rate caused by CME and inhibit the expression of activated caspase-3, which were activated during CME in rats, indicating that metoprolol-related improvement of cardiac function after CME is associated with the blockade of myocardial apoptosis and with the inhibition of the expression of activated caspase-3. Our study is the first to illustrate the effect of metoprolol on myocardial apoptosis and caspase-3 activated after coronary microembolization.

LIMITATIONS

First, there is a need for a suitable animal model

**Figure 4.** Graph showing effect of metoprolol on apoptosis following CME. Myocardial apoptosis after CME (TUNEL assay) was detected primarily in the myocardial microinfarction foci and the peripheral zones. In control animals, myocardial apoptosis was occasionally found in the subendocardium and papillary muscles. Data are means ± SD. Compared with the control group, \( P < 0.05 \); compared with the CME group, \( \# P < 0.05 \).

**Figure 5.** Effect of metoprolol on caspase-3 expression following CME. A: The relative expression levels of activated caspase-3 protein were determined by using western blot; the IA values were normalized to GAPDH expression levels. Lanes 1, 2, and 3 in the representative gel show caspase-3 expression in the control, CME (after 6 hours), and metoprolol groups, respectively. B: The data obtained \( (n = 10) \) were expressed and compared between the groups as means ± SD values, herein presented graphically. Compared with the control group, \( * P < 0.05 \); compared with the CME group, \( \# P < 0.05 \).
that mimics the real clinical scenario of CME as closely as possible. The polymer microspheres do not have the biochemical characteristics of natural microemboli including platelets, endothelial cells, and plaque debris with cholesterol crystals. Second, an open-chest operation will also generate an impact on apoptosis.

In summary, in our study myocardial apoptosis was increased in CME rat lesion tissues, as evidenced by TUNEL staining and activation of caspase-3. Treatment with metoprolol significantly attenuated CME induced myocardial injury and improved cardiac function. Thus, metoprolol could protect the myocardium through the inhibition of the apoptosis and provide theoretical basis for the clinical prevention and therapy of CME.

**Funding:** This study was supported by a grant from the National Natural Science Foundation of China (30760262/C030313).

**Ethical approval:** The present study was approved the Animal Care and Use Committee of First Affiliated Hospital of Guangxi Medical University, Nanning, China.

**Conflicts of interest:** The authors have no competing interests relevant to the present study.

**Contributors:** Su Q proposed and wrote the paper. All authors contributed to editing the final manuscript for content and style.

**REFERENCES**

1. Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schulz R, et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation 2009; 120: 1822–1836.

2. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202–1209.

3. Kretzschmar D, Jung C, Otto S, Utschig S, Hartmann M, Lehmann T, et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study. Cardiovasc Ultrasound 2012; 10: 21.

4. Dörge H, Neumann T, Behrends M, Skyschally A, Schulz R, Kasper C, et al. Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. Am J Physiol Heart Circ Physiol 2000; 279: H2587–2592.

5. Carlsson M, Martin AJ, Ursell PC, Saloner D, Saeed M. Magnetic resonance imaging quantification of left ventricular dysfunction following coronary microembolization. Magn Reson Med 2009; 61: 595–602.

6. Waksman R, Douglas JS, Scott NA, Ghazzal ZM, Yee-Peterson J, King SB, 3rd, et al. Distal embolization is common after directional atherectomy in coronary arteries and saphenous vein grafts. Am Heart J 1995; 129: 430–435.

7. Grube E, Schofer J Jü, Webb J, Schuler G, Colombbo A, Sievert H, et al. Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. Am J Cardiol 2002; 89: 941–945.

8. Lu Y, Li L, Zhao X, Huang W, Wen W. Beta blocker metoprolol protects against contractile dysfunction in rats after coronary microembolization by regulating expression of myocardial inflammatory cytokines. Life Sci 2011; 88: 1009–1015.

9. Wang FW, Osman A, Otero J, Stouffer GA, Wamxan S, Afzal A, et al. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 2003; 107: 2914–2919.

10. Uretsky BF, Birnbaum Y, Osman A, Gupta R, Paniagua O, Chamoun A, et al. Distal myocardial protection with intracoronary beta blocker when added to a Gp IIB/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome. Catheter Cardiovasc Interv 2008; 72: 488–497.

11. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI. Beneficial effects of chronic pharmacological manipulation of beta-adrenoceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 2004; 110: 1083–1090.

12. Seqqat R, Guo X, Rafiq K, Kolpakov MA, Guo J, Koch WJ, et al. Betal-adenrenergic receptors promote focal adhesion signaling downregulation and myocyte apoptosis in acute volume overload. J Mol Cell Cardiol 2012; 53: 240–249.

13. Thielmann M, Dörge H, Martin C, Belosorov S, Schwane U, van De Sand A, et al. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res 2002; 90: 807–813.

14. Li L, Li DH, Qu N, Wen WM, Huang WQ. The role of ERK1/2 signaling pathway in coronary microembolization-induced rat myocardium inflammation and injury. Cardiology 2010; 117: 207–215.

15. Kalenikova EI, Gorodetskaya EA, Zacharova NV, Shechter AB, Medvedev OS. Perindopril effects on angiotensin I elimination in lung after experimental myocardial injury induced by intracoronary microembolization in rats. J Cardiovasc Pharmacol 1998; 32: 608–615.

16. Zhang QY, Ge JB, Chen JZ, Zhu JH, Zhang LH, Lau CP, et al. Mast cell contributes to cardiomyocyte apoptosis after coronary microembolization. J Histochem Cytochem 2006; 54: 515–523.

17. Grund F, Sommerschild HT, Lyberg T, Kirkeboen KA, Ilebekk A. Microembolization in pigs: effects on coronary blood flow and myocardial ischemic tolerance. Am J Physiol 1999; 277: H533–542.

18. Skyschally A, Schulz R, Erbel R, Heusch G. Reduced coronary and inotropic reserves with coronary microembolization. Am J Physiol Heart Circ Physiol 2002; 282: H611–614.

19. Miura M, Thomas R, Ganz W, Sokol T, Shell WE, Toshimitsu T, et al. The effect of delay in propranolol administration on reduction of myocardial infarct size after experimental coronary artery occlusion in dogs. Circulation 1979; 59: 1148–1157.

20. Holleyman CR, Larson DF. Apoptosis in the ischemic reperfused myocardium. Perfusion 2001; 16: 491–502.

21. Li X, Luo R, Jiang R, Meng X, Wu X, Zhang S, et al. The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. BMC Cardiovasc Disord 2013; 13: 8.

22. Wu L, Xi Z, Guo R, Liu S, Yang S, Liu D, et al. Exogenous ARC down-regulates caspase-3 expression and inhibits apoptosis of broiler chicken cardiomyocytes exposed to hydrogen peroxide. Avian Pathol 2013; 42: 32–37.

Received January 6, 2013
Accepted after revision May 6, 2013

www.wjem.org